About us
Our
Vision
A bright future for patients with rare kidney disease
Our
Mission
Transforming the treatment landscape for patients with ADPKD and other rare diseases through novel scientific approaches
our approach
Mironid® is currently building and progressing a pipeline of drug development programmes that are targeted at cAMP degrading phosphodiesterase enzymes. The goal is to generate novel and differentiated therapies for a range of diseases with high unmet medical need.
Current and Future Growth Ambitions
our investors
